The present application relates generally to systems that process high-melting-point liquids, and, more particularly, to a system for identifying and quantifying chemical components in a high-melting-point liquid.
Corrosion of metal parts in a molten salt conduit containing a molten salt flow may be caused by water (H2O), oxygen (O2), and/or other impurities in the molten salt. Corrosion rates depend on the level(s) of impurities in the molten salt. Accordingly, progress towards a working nuclear reactor that utilizes a high-melting point liquid (e.g., molten salt) must be supported by the ability to identify and quantify potentially corrosive components (e.g., chemical components) in the high-melting point liquid.
Apparatus, systems, and methods for elemental analysis of a high-melting-point liquid are described herein. Such a high-melting-point liquid may be or include molten salt, molten sodium, molten lead, the like, or any combination thereof. Specifically, the present disclosure facilitates real-time identification and quantification of components in the high-melting-point liquid, which is a critical step in achieving regulatory approval for a nuclear reactor utilizing the high-melting-point liquid (e.g., the molten salt). Corrosion of metal parts in contact with a molten salt flow may be caused by water (H2O), oxygen (O2), and/or other impurities in the molten salt. The present disclosure enables operators to measure: the components in the high-melting-point liquid (e.g., molten salt); the concentration(s) of water (H2O) and oxygen (O2) in the molten salt; and/or other impurity levels in the high-melting-point liquid. Equipped with this information, among other things, operators are able to determine how certain metals (e.g., alloys) behave when in contact with the high-melting-point liquid (with and without impurities), and prevent, or at least reduce, corrosion by monitoring and setting alarms for any situation in which the concentrations of the impurities and/or other components in the high-melting-point liquid stray outside of safe operating levels.
Referring to
The nebulizer assembly 136 also includes a nebulizer 130. The nebulizer 130 is contained within the heater 120. The evacuator 115 provides a connection between the molten liquid conduit 105 and the nebulizer 130. The nebulizer 130 is configured to receive the volume of the high-melting-point liquid 165 delivered from the evacuator 115. The nebulizer assembly 136 also includes a heat exchanger 135. The heat exchanger 135 is contained within the heater 120. The heater 120 is configured to heat the evacuator 115, the nebulizer 130, and the heat exchanger 135 to keep the high-melting-point liquid from freezing. As shown in
Referring still to
In some embodiments, in addition to, or instead of, the interface apparatus 140, the FAAS 145, the ICP torch 150, the ICP-MS 155, and the ICP-OES 160, the instrument(s) 137 may be or include one or more other components, such as, for example, other analytical instrumentation configured to receive the aerosolized volume of the high-melting-point liquid 165 from the nebulizer assembly 136 and to determine the chemical contents of the aerosolized high-melting-point liquid.
In operation, the molten liquid conduit 105 contains a high-melting-point liquid 165. A volume of the high-melting-point liquid 165 is communicated from the molten liquid conduit 105 to the nebulizer assembly 136, more specifically to the evacuator 115, as indicated by arrows 170a-b. In addition to receiving the volume of the high-melting-point liquid 165 from the molten liquid conduit 105, as indicated by the arrow 170b, the evacuator 115 also receives gas (e.g., argon) from the gas source 125, as indicated by arrow 175. In response to the evacuator 115 receiving the volume of the high-melting-point liquid 165 from the molten liquid conduit 105 and receiving the gas (e.g., argon) from the gas source 125, the evacuator 115 discharges the received volume of the high-melting-point liquid 165 into the nebulizer 130, as indicated by arrow 180. The heater 120 heats the evacuator 115, the nebulizer 130, and the heat exchanger 135 to keep the received volume of the high-melting-point liquid 165 from freezing. The nebulizer 130 also receives gas (e.g., argon) from the gas source 125 (or another gas source) via the heat exchanger 135, as indicated by arrows 185a-b. In response to the nebulizer 130 receiving the volume of the high-melting-point liquid 165 from the evacuator 115 and the gas (e.g., argon) from the gas source 125, the nebulizer 130 aerosolizes the received volume of the high-melting-point liquid 165 and communicates the aerosolized high-melting-point liquid to the interface apparatus 140, as indicated by arrow 190. Before, during, or after the nebulizer 130 aerosolizes the received volume of the high-melting-point liquid 165, the vacuum source 138 applies a reduced or negative gas pressure to the evacuator 115, as indicated by arrow 195. The reduced or negative gas pressure applied to the evacuator 115 withdraws any non-aerosolized remainder of the high-melting-point liquid from the nebulizer 130 and back into the evacuator 115, as indicated by arrow 200. In some embodiments, withdrawal of the non-aerosolized remainder of the high-melting-point liquid from the nebulizer 130 and back into the evacuator 115 prevents, or at least reduces, cooling and/or freezing of the non-aerosolized remainder of the high-melting-point liquid within the nebulizer 130, which would otherwise be difficult to clean out.
The interface apparatus 140 sweeps the aerosolized high-melting-point liquid into the FAAS 145, as indicated by arrow 205. The FAAS 145 identifies and quantifies element(s) in the aerosolized high-melting-point liquid. In addition, or instead, the interface apparatus 140 sweeps the aerosolized high-melting-point liquid into the ICP torch 150 (or another interface apparatus), as indicated by arrow 210. The ICP torch 150 heats the aerosolized high-melting-point liquid in a plasma. As a result, the ICP torch emits electromagnetic radiation (e.g., in the visible, ultraviolet, and near-infrared ranges of the electromagnetic spectrum) and gas-phase atoms/ions. In some embodiments, as in
The operation of the system 100 enables operators to identify and quantify potentially corrosive components such as water (H2O), oxygen (O2), and/or other impurities in the high-melting-point liquid 165. Once such potentially corrosive components are identified and quantified, operators can determine how certain metals (e.g., alloys) behave when in contact with the high-melting-point liquid (with and without impurities). Based on this information, operators can monitor the concentration(s) of such potentially corrosive components in the high-melting-point liquid 165 and set alarms for any situation in which the concentration(s) of such potentially corrosive components in the high-melting-point liquid 165 stray outside of safe operating levels. Such alarms notify operators when it is necessary to take steps to reduce the concentration(s) of such potentially corrosive components in the high-melting-point liquid 165. In addition, based on the monitoring of the concentration(s) of such potentially corrosive components in the high-melting-point liquid 165 over time, operators can plan for the maintenance, repair, remediation, and/or replacement of critical components of the molten liquid conduit 105 (or other components in contact with the high-melting-point liquid 165) before failure of such critical components occurs.
As mentioned above, the molten liquid conduit 105 can be part of a molten salt loop associated with a nuclear reactor, in which case the system 100 supports the reliability of the nuclear reactor. For example, the system 100 may enable operators of the nuclear reactor to monitor fuel concentration(s) (e.g., uranium-235 or other fuel isotopes), which must remain at certain levels for the nuclear reactor to function properly. For another example, the system 100 may enable operators of the nuclear reactor to monitor fission products (e.g., thorium-231). For yet another example, the system 100 may enable operators of the nuclear reactor to monitor medically useful isotopes (e.g., molybdenum-99), which can then be removed. Furthermore, although described as including the FAAS 145, the ICP-MS 155, and the ICP-OES 160, in addition, or instead, the system 100 may include other analytical instrumentation configured to receive the aerosolized high-melting-point liquid from the nebulizer 130 and to determine the chemical contents of the aerosolized high-melting-point liquid.
Referring to
Referring to
The evacuator 115 also includes a gas conduit 260. In some embodiments, the gas conduit 260 includes a tube 265 and a fitting 270. The tube 265 defines opposing end portions 275a and 275b and has a length L1. In some embodiments, the tube 265 extends through the end portion 245a of the fluid vessel 230. For example, the end portion 275a of the tube 265 may extend proximate the end portion 245a of the fluid vessel 230. In some embodiments, the tube 265 is a 0.25 in. O.D. SS316 tube. The fitting 270 is connected to the tube 265 at the end portion 275a. In some embodiments, the fitting 270 is a Yor-Lok 90° elbow fitting for 0.25-in. O.D. tube. Alternatively, the tube 265 may be omitted from the evacuator 115 and the fitting 270 may instead be connected directly to the end portion 245a of the fluid vessel 230 to communicate with the internal cavity 235 of the fluid vessel 230.
The evacuator 115 also includes a molten liquid conduit 280. In some embodiments, the molten liquid conduit 280 includes a tube 285 and a fitting 290. The tube 285 defines opposing end portions 295a and 295b and has a length L2. The tube 285 extends through the end portion 245a of the fluid vessel 230 and into the internal cavity 235. The length L2 is greater than the length L1. As a result, the end portion 295b of the tube 285 extends closer to the end portion 245b of the fluid vessel 230, and farther from the end portion 245a of the fluid vessel 230, than the end portion 275b of the tube 265. For example, the end portion 295b of the tube 285 may extend within the internal cavity 235 proximate the end portion 245b of the fluid vessel 230. In contrast, the end portion 295a of the tube 285 extends outside the fluid vessel 230. In some embodiments, the tube 285 is a 0.25 in. O.D. SS316 tube. The fitting 290 is connected to the tube 285 at the end portion 295a. In some embodiments, the fitting 290 is a Yor-Lok 90° elbow fitting for 0.25-in. O.D. tube.
During the operation of the system 100, high-melting-point liquid 296 is communicated from the molten liquid conduit 105 to the evacuator 115 via the molten liquid conduit 225a (shown in
Referring to
The nebulizer 130 also includes a gas conduit 335. In some embodiments, the gas conduit 335 includes a tube 340 and a fitting 345. The tube 340 defines opposing end portions 350a and 350b and has an outer diameter D1. The tube 340 extends through the lid 315 and into the internal cavity 305 of the fluid vessel 300. For example, the end portion 350b of the tube 340 may extend within the internal cavity 305 of the fluid vessel 300 proximate the end portion 320b of the jar 310. In contrast, the end portion 350a of the tube 340 extends outside the fluid vessel 300. The fitting 345 is connected to the tube 340 at the end portion 350a. The nebulizer 130 also includes a jet 355. The jet 355 is connected to the tube 340 at the end portion 350b. The jet 355 has an outer diameter D2. The outer diameter D2 is greater than the outer diameter D1. The jet 355 includes spray holes 360 distributed (e.g., evenly) therearound.
The nebulizer 130 also includes an aerosol outlet 365. In some embodiments, the aerosol outlet 365 includes a curved tube 370 coupled to the nebulizer 130 so as to communicate with the internal cavity 305 of the fluid vessel 300. For example, the curved tube 370 of the aerosol outlet 365 may be connected to the lid 315 of the nebulizer 130. The aerosol outlet 365 is configured to sweep away the aerosolized high-melting-point liquid. The curved tube 370 of the aerosol outlet 365 defines an enlarged flow passageway as compared to the tube 340 of the gas conduit 335. The enlarged flow passageway of the aerosol outlet 365 is configured to accommodate the increased volume of the high-melting-point liquid after it has been aerosolized.
During the operation of the system 100, the high-melting-point liquid 296 is communicated from the evacuator 115 to the nebulizer 130 via the molten liquid conduit 225c (shown in
In some embodiments, the nebulizer 130 may be omitted and replaced with another nebulizer in which the pump 110 generates the pressure needed to force the high-melting-point liquid 296 through a nozzle to create the aerosolized high-melting-point liquid. In other embodiments, the nebulizer 130 may be omitted and replaced with yet another nebulizer utilizing a different nebulization process such as, for example, pneumatic nebulization, ultrasonic nebulization, the like, or a combination thereof. In some embodiments, in addition, or instead, the evacuator 115 may be omitted from the nebulizer assembly 136.
Referring to
Referring to
Referring to
Referring to
Referring to
A valve 530a is operably coupled between the outlet 528a of the molten liquid conduit 105 and the evacuator 115′, which valve 530a is actuable between open and closed positions to either permit or block flow of the high-melting-point liquid 165 from the outlet 528a of the molten liquid conduit 105 and into the evacuator 115′. The valve 530a is a two-way valve. Similarly, a valve 530b is operably coupled between the evacuator 115′ and the nebulizer 130, which valve 530b is actuable between open and closed positions to either permit or block flow of the high-melting-point liquid 165 from the evacuator 115′ to the nebulizer 130, and vice versa. The valve 530b is a two-way valve.
The nebulizer assembly 136′ also includes a gas source 125′, which gas source 125′ is similar to the gas source 125 except that, rather than delivering gas directly to the evacuator 115, as in
The valve 530c is a three-way valve actuable between: a first open position in which the valve 530c permits fluid communication between the gas source 125′ (via the heat exchanger 135) and the evacuator 115′ while blocking fluid communication between the vacuum source 138′ and the evacuator 115′; a second open position in which the valve 530c permits fluid communication between the vacuum source 138′ and the evacuator 115′ while blocking fluid communication between the gas source 125′ and the evacuator 115′; and a closed position in which the valve 530c blocks fluid communication between the gas source 125′ and the evacuator 115′ while also blocking fluid communication between the vacuum source 138′ and the evacuator 115′. Alternatively, the valve 530c may be omitted and replaced by a pair of two-way valves (not shown), one of which is actuable between open and closed positions to permit or block fluid communication between the gas source 125′ and the evacuator 115′, and the other of which is actuable between open and closed positions to permit or block fluid communication between the vacuum source 138′ and the evacuator 115′.
A valve 530d is operably coupled between the evacuator 115′ and an inlet 528b of the molten liquid conduit 105, which valve 530d is actuable between open and closed positions to either permit or block flow of the high-melting-point liquid 165 from the evacuator 115′ back into the molten liquid conduit 105 via the inlet 528b. The valve 530d is a two-way valve. Alternatively, the valves 530a and 530d may be omitted and replaced by a three-way valve similar in structure and operation to the valve 530c.
In some embodiments, as in
Table 1 illustrates various operational configurations for the valves 530a-d, as will be described in further detail below.
Referring to
At a step 533b, the volume of high-melting-point liquid with which the evacuator 115′ is filled is permitted to flow from the evacuator 115′ to the nebulizer 130. The step 533b can be executed by actuating the valves 530a-d to Configuration B, in which the valves 530a and 530d are closed and the valves 530b and 530c are open, as shown above in Table 1. More particularly, in Configuration B, the three-way valve 530c is actuated to the first open position described above, in which the valve 530c permits fluid communication between the gas source 125′ (via the heat exchanger 135) and the evacuator 115′ while blocking fluid communication between the vacuum source 138′ and the evacuator 115′. Actuating the valves 530a-d to Configuration B allows pressurized gas from the gas source 125′ to displace the volume of high-melting-point liquid from the evacuator 115′ into the nebulizer 130.
At a step 533c, at least a portion of the volume of the high-melting-point liquid in the nebulizer 130 is aerosolized, using the nebulizer 130. The structure and operation of the nebulizer 130 are described in detail above. Next, at a step 533d, the aerosolized high-melting-point liquid is permitted to flow to the instrument(s) 137 for chemical analysis. The structure and operation of the instrument(s) 137 are described in detail above, according to one or more embodiments.
At a step 533e, any remaining non-aerosolized high-melting-point liquid is evacuated from the nebulizer 130 using the evacuator 115′. The step 533e can be executed by actuating the valves 530a-d to Configuration C, in which the valves 530a and 530d are closed and the valves 530b and 530c are open, as shown above in Table 1. More particularly, in Configuration C, the three-way valve 530c is actuated to the second open position described above, in which the valve 530c permits fluid communication between the vacuum source 138′ and the evacuator 115′ while blocking fluid communication between the gas source 125′ and the evacuator 115′. Actuating the valves 530a-d to Configuration C allows decreased or negative gas pressure from the vacuum source 138′ to draw any remaining volume of high-melting-point liquid in the nebulizer 130 back into the evacuator 115′.
Finally, at a step 533f, the evacuated non-aerosolized high-melting-point liquid is permitted to flow from the evacuator 115′ back to the molten liquid conduit 105. The step 533f can be executed by actuating the valves 530a-d to Configuration D, in which the valves 530a and 530b are closed and the valves 530c and 530d are open, as shown above in Table 1. More particularly, in Configuration D, the three-way valve 530c is actuated to the first open position described above, in which the valve 530c permits fluid communication between the gas source 125′ (via the heat exchanger 135) and the evacuator 115′ while blocking fluid communication between the vacuum source 138′ and the evacuator 115′. Actuating the valves 530a-d to Configuration D allows pressurized gas from the gas source 125′ to displace the volume of high-melting-point liquid from the evacuator 115′ back into the molten liquid conduit 105, via the valve 530d.
Referring to
Referring to
A system has been described herein. The system generally includes a molten liquid conduit; a nebulizer assembly operably coupled to the molten liquid conduit and adapted to receive, from the molten liquid conduit, a high-melting-point liquid; wherein the nebulizer assembly is further adapted to aerosolize at least a portion of the high-melting-point liquid received from the molten liquid conduit; one or more instruments operably coupled to the nebulizer assembly and adapted to receive the aerosolized high-melting-point liquid from the nebulizer, wherein the one or more instruments are further adapted to chemically analyze the aerosolized high-melting-point liquid. In one or more embodiments, the nebulizer assembly includes: a nebulizer including a first fluid vessel in which the nebulizer is adapted to aerosolize the at least a portion of the high-melting-point liquid received from the molten liquid conduit. In one or more embodiments, the nebulizer assembly further includes: an evacuator including a second fluid vessel adapted to receive, from the molten liquid conduit, the high-melting-point liquid, the second fluid vessel being operably coupled to the first fluid vessel of the nebulizer. In one or more embodiments, the nebulizer assembly further includes: a valve operably coupled between, and in fluid communication with, the molten liquid conduit and the second fluid vessel of the evacuator. In one or more embodiments, the nebulizer assembly further includes a gas source adapted to communicate gas into the evacuator to thereby deliver the received high-melting-point liquid from the second fluid vessel of the evacuator into the first fluid vessel of the nebulizer. In one or more embodiments, the nebulizer assembly further includes a valve operably coupled between, and in fluid communication with, the first fluid vessel of the nebulizer and the second fluid vessel of the evacuator. In one or more embodiments, the nebulizer assembly further includes a vacuum source adapted to apply decreased or negative gas pressure from the vacuum source to the evacuator to thereby withdraw a non-aerosolized portion of the high-melting-point liquid from the first fluid vessel of the nebulizer and back into the second fluid vessel of the evacuator. In one or more embodiments, the nebulizer assembly further includes a valve operably coupled between, and in fluid communication with, the first fluid vessel of the nebulizer and the second fluid vessel of the evacuator. In one or more embodiments, the gas source is further adapted to communicate gas into the evacuator to thereby deliver the withdrawn non-aerosolized portion of the high-melting-point liquid from the evacuator and back into the molten liquid conduit. In one or more embodiments, the nebulizer assembly further includes a valve operably coupled between, and in fluid communication with, the second fluid vessel of the evacuator and the molten liquid conduit. In one or more embodiments, the nebulizer assembly includes: a nebulizer adapted to aerosolize the at least a portion of the received high-melting-point liquid, which nebulizer includes a vibrating mesh mounted to a vibration source; and a power source operably coupled to, and adapted to electrify, the vibration source to thereby cause the vibration source to vibrate. In one or more embodiments, the nebulizer assembly further includes a gas source adapted to communicate gas into the aerosolized high-melting-point liquid to deliver the aerosolized high-melting-point liquid from the nebulizer into the one or more instruments.
A method has also been described herein. The method generally includes: receiving, into a nebulizer assembly, a high-melting-point liquid from a molten liquid conduit; aerosolizing, using the nebulizer assembly, at least a portion of the received high-melting-point liquid; delivering, into one or more instruments, the aerosolized high-melting-point liquid from the nebulizer; and chemically analyzing, using the one or more instruments, the aerosolized high-melting-point liquid. In one or more embodiments, the nebulizer assembly includes a nebulizer adapted to aerosolize the at least a portion of the received high-melting-point liquid, which nebulizer includes a first fluid vessel. In one or more embodiments, the nebulizer assembly further includes an evacuator adapted to receive the high-melting-point liquid from the molten liquid conduit, which evacuator includes a second fluid vessel operably coupled to the first fluid vessel of the nebulizer. In one or more embodiments, the nebulizer assembly further includes a valve operably coupled between, and in fluid communication with, the molten liquid conduit and the second fluid vessel of the evacuator; and wherein receiving, into the evacuator, the high-melting-point liquid from the molten liquid conduit includes opening the valve. In one or more embodiments, the method further includes: delivering the received high-melting-point liquid from the second fluid vessel of the evacuator into the first fluid vessel of the nebulizer. In one or more embodiments, the nebulizer assembly further includes a gas source; and wherein delivering the received high-melting-point liquid from the second fluid vessel of the evacuator into the first fluid vessel of the nebulizer includes communicating gas from the gas source into the evacuator. In one or more embodiments, the nebulizer assembly further includes a valve operably coupled between, and in fluid communication with, the first fluid vessel of the nebulizer and the second fluid vessel of the evacuator; and wherein delivering the received high-melting-point liquid from the second fluid vessel of the evacuator into the first fluid vessel of the nebulizer further includes opening the valve. In one or more embodiments, the method further includes: withdrawing a non-aerosolized portion of the high-melting-point liquid from the first fluid vessel of the nebulizer and back into the second fluid vessel of the evacuator. In one or more embodiments, the nebulizer assembly further includes a vacuum source; and wherein withdrawing the non-aerosolized portion of the high-melting-point liquid from the first fluid vessel of the nebulizer and back into the second fluid vessel of the evacuator includes applying, to the evacuator, decreased or negative gas pressure from the vacuum source. In one or more embodiments, the nebulizer assembly further includes a valve operably coupled between, and in fluid communication with, the first fluid vessel of the nebulizer and the second fluid vessel of the evacuator; and wherein withdrawing the non-aerosolized portion of the high-melting-point liquid from the first fluid vessel of the nebulizer and back into the second fluid vessel of the evacuator further includes opening the valve. In one or more embodiments, the method further includes: delivering the withdrawn non-aerosolized portion of the high-melting-point liquid from the evacuator and back into the molten liquid conduit. In one or more embodiments, the nebulizer assembly further includes a gas source; and wherein delivering the withdrawn non-aerosolized portion of the high-melting-point liquid from the evacuator and back into the molten liquid conduit includes communicating gas from the gas source into the evacuator. In one or more embodiments, the nebulizer assembly further includes a valve operably coupled between, and in fluid communication with, the second fluid vessel of the evacuator and the molten liquid conduit; and wherein delivering the withdrawn non-aerosolized portion of the high-melting-point liquid from the evacuator and back into the molten liquid conduit further includes opening the valve. In one or more embodiments, the nebulizer assembly includes: a nebulizer adapted to aerosolize the at least a portion of the received high-melting-point liquid, which nebulizer includes a vibrating mesh mounted to a vibration source; and a power source operably coupled to, and adapted to electrify, the vibration source; wherein aerosolizing the at least a portion of the received high-melting-point liquid includes electrifying, using the power source, the vibration source to thereby cause the vibration source to vibrate. In one or more embodiments, the nebulizer assembly further includes a gas source; and wherein delivering, into the one or more instruments, the aerosolized high-melting-point liquid from the nebulizer includes communicating gas from the gas source into the nebulizer.
It is understood that variations may be made in the foregoing without departing from the scope of the present disclosure.
In several embodiments, the elements and teachings of the various embodiments may be combined in whole or in part in some or all of the embodiments. In addition, one or more of the elements and teachings of the various embodiments may be omitted, at least in part, and/or combined, at least in part, with one or more of the other elements and teachings of the various embodiments.
Any spatial references, such as, for example, “upper,” “lower,” “above,” “below,” “between,” “bottom,” “vertical,” “horizontal,” “angular,” “upwards,” “downwards,” “side-to-side,” “left-to-right,” “right-to-left,” “top-to-bottom,” “bottom-to-top,” “top,” “bottom,” “bottom-up,” “top-down,” etc., are for the purpose of illustration only and do not limit the specific orientation or location of the structure described above.
In several embodiments, while different steps, processes, and procedures are described as appearing as distinct acts, one or more of the steps, one or more of the processes, and/or one or more of the procedures may also be performed in different orders, simultaneously and/or sequentially. In several embodiments, the steps, processes, and/or procedures may be merged into one or more steps, processes and/or procedures.
In several embodiments, one or more of the operational steps in each embodiment may be omitted. Moreover, in some instances, some features of the present disclosure may be employed without a corresponding use of the other features. Moreover, one or more of the above-described embodiments and/or variations may be combined in whole or in part with any one or more of the other above-described embodiments and/or variations.
Although several embodiments have been described in detail above, the embodiments described are illustrative only and are not limiting, and those skilled in the art will readily appreciate that many other modifications, changes and/or substitutions are possible in the embodiments without materially departing from the novel teachings and advantages of the present disclosure. Accordingly, all such modifications, changes, and/or substitutions are intended to be included within the scope of this disclosure as defined in the following claims. In the claims, any means-plus-function clauses are intended to cover the structures described herein as performing the recited function and not only structural equivalents, but also equivalent structures. Moreover, it is the express intention of the applicant not to invoke 35 U.S.C. § 112(f) for any limitations of any of the claims herein, except for those in which the claim expressly uses the word “means” together with an associated function.
This application claims the benefit of the filing date of, and priority to, U.S. Application No. 62/932,887, filed Nov. 8, 2019, the entire disclosure of which is hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4539846 | Grossman | Sep 1985 | A |
6125912 | Branagan et al. | Oct 2000 | A |
6143431 | Webster | Nov 2000 | A |
6258185 | Branagan et al. | Jul 2001 | B1 |
6699455 | Bulan et al. | Mar 2004 | B2 |
6710335 | Ellson et al. | Mar 2004 | B2 |
6841140 | Nishmimura et al. | Jan 2005 | B2 |
8636892 | Koehl et al. | Jan 2014 | B2 |
8642954 | Ivaldi et al. | Feb 2014 | B2 |
8746440 | Williamson et al. | Jun 2014 | B2 |
8771482 | Bailey et al. | Jul 2014 | B2 |
8900439 | Wiedmeyer et al. | Dec 2014 | B2 |
8956524 | Wiedmeyer et al. | Feb 2015 | B2 |
8968547 | Loewen et al. | Mar 2015 | B2 |
9017527 | Wiedmeyer et al. | Apr 2015 | B2 |
9150975 | Berger et al. | Oct 2015 | B2 |
9287099 | Otsuka et al. | Mar 2016 | B2 |
9299464 | Venneri | Mar 2016 | B2 |
9305673 | Heinold et al. | Apr 2016 | B2 |
9475706 | Policke et al. | Oct 2016 | B2 |
9620248 | Venneri | Apr 2017 | B2 |
9941025 | Ahlfeld et al. | Apr 2018 | B2 |
9968899 | Gellaboina | May 2018 | B1 |
10032528 | Venneri | Jul 2018 | B2 |
10056160 | LeBlanc | Aug 2018 | B2 |
10109382 | Hackett et al. | Oct 2018 | B2 |
10141079 | Czerwinski et al. | Nov 2018 | B2 |
10109378 | Snead | Dec 2018 | B2 |
10221499 | Miller et al. | Mar 2019 | B2 |
10280527 | Loewen et al. | May 2019 | B2 |
10438705 | Cheatham, III | Oct 2019 | B2 |
10475543 | Venneri | Nov 2019 | B2 |
10566096 | Czerwinski | Feb 2020 | B2 |
10573416 | Venneri | Feb 2020 | B2 |
10685750 | Eichel et al. | Jun 2020 | B2 |
10878971 | Venneri | Dec 2020 | B2 |
11101048 | Venneri | Aug 2021 | B2 |
11136245 | Benson | Oct 2021 | B2 |
11170901 | Cheatham, III | Nov 2021 | B2 |
11189383 | Snead | Nov 2021 | B2 |
11200991 | LeBlanc | Dec 2021 | B2 |
11286172 | Russell et al. | Mar 2022 | B2 |
11373765 | Czerwinski | Jun 2022 | B2 |
11501883 | Eichel et al. | Nov 2022 | B2 |
20060000071 | Lin | Jan 2006 | A1 |
20080173131 | Withers | Jul 2008 | A1 |
20090046825 | Dulka et al. | Feb 2009 | A1 |
20120325925 | Ivaldi | Dec 2012 | A1 |
20150040727 | Kosslow | Feb 2015 | A1 |
20150310948 | Venneri | Oct 2015 | A1 |
20160189812 | Czerwinski | Jun 2016 | A1 |
20160189813 | Cisneros, Jr. | Jun 2016 | A1 |
20160217874 | Dewan et al. | Jul 2016 | A1 |
20170045423 | Launiere | Feb 2017 | A1 |
20170271033 | Dodson et al. | Sep 2017 | A1 |
20170292179 | Hackett | Oct 2017 | A1 |
20170294241 | Dodson et al. | Oct 2017 | A1 |
20170294242 | Simpson | Oct 2017 | A1 |
20170301413 | Cisneros, Jr. | Oct 2017 | A1 |
20170301418 | Dodson et al. | Oct 2017 | A1 |
20180254109 | Cheatham, III et al. | Sep 2018 | A1 |
20190015806 | Gellaboina | Jan 2019 | A1 |
20190057783 | LeBlanc | Feb 2019 | A1 |
20190139665 | Czerwinski et al. | May 2019 | A1 |
20190371482 | Benson | Dec 2019 | A1 |
20200087156 | Kelleher | Mar 2020 | A1 |
20200122109 | Kruizenga et al. | Apr 2020 | A1 |
20200161015 | Czerwinski et al. | May 2020 | A1 |
20200180975 | Benson | Jun 2020 | A1 |
20210130181 | Brown et al. | May 2021 | A1 |
20210210235 | Venneri | Jul 2021 | A1 |
20220005617 | Snead | Jan 2022 | A1 |
20220051818 | Cisneros, Jr. | Feb 2022 | A1 |
20220139577 | Cisneros, Jr. et al. | May 2022 | A1 |
20220139578 | Venneri et al. | May 2022 | A1 |
20220250936 | Benson | Aug 2022 | A1 |
20230104365 | Eichel et al. | Apr 2023 | A1 |
Number | Date | Country |
---|---|---|
102795601 | Nov 2012 | CN |
203080087 | Jul 2013 | CN |
102967494 | Apr 2015 | CN |
103714371 | May 2016 | CN |
104090004 | May 2016 | CN |
106128533 | Nov 2016 | CN |
106283112 | Jan 2017 | CN |
106425315 | Feb 2017 | CN |
107230506 | Oct 2017 | CN |
106158053 | Nov 2017 | CN |
107344726 | Nov 2017 | CN |
106180254 | Jun 2018 | CN |
108172318 | Jun 2018 | CN |
108389634 | Aug 2018 | CN |
109141969 | Jan 2019 | CN |
109207128 | Jan 2019 | CN |
105838339 | Mar 2019 | CN |
109509562 | Mar 2019 | CN |
106621429 | Apr 2019 | CN |
106840765 | Apr 2019 | CN |
109671510 | Apr 2019 | CN |
106902526 | Jun 2019 | CN |
106477618 | Jul 2019 | CN |
110042434 | Jul 2019 | CN |
105420737 | Sep 2019 | CN |
105463306 | Sep 2019 | CN |
106221678 | Sep 2019 | CN |
108179432 | Sep 2019 | CN |
110194494 | Sep 2019 | CN |
107469628 | Oct 2019 | CN |
108109710 | Oct 2019 | CN |
209496626 | Oct 2019 | CN |
108231224 | Dec 2019 | CN |
108511089 | Dec 2019 | CN |
106517097 | Feb 2020 | CN |
110783010 | Feb 2020 | CN |
210803355 | Jun 2020 | CN |
108956744 | Jul 2020 | CN |
109637682 | Sep 2020 | CN |
106957636 | Oct 2020 | CN |
110203886 | Oct 2020 | CN |
109011696 | Dec 2020 | CN |
112062567 | Dec 2020 | CN |
112111251 | Dec 2020 | CN |
112284170 | Jan 2021 | CN |
112322939 | Feb 2021 | CN |
112357885 | Feb 2021 | CN |
108956443 | Mar 2021 | CN |
109097001 | Mar 2021 | CN |
110689984 | Mar 2021 | CN |
109231241 | Apr 2021 | CN |
110444311 | May 2021 | CN |
112778012 | May 2021 | CN |
108088813 | Jun 2021 | CN |
112946046 | Jun 2021 | CN |
113174240 | Jul 2021 | CN |
213707743 | Jul 2021 | CN |
109680282 | Sep 2021 | CN |
113372886 | Sep 2021 | CN |
112391653 | Nov 2021 | CN |
113630582 | Nov 2021 | CN |
111334258 | Dec 2021 | CN |
113860350 | Dec 2021 | CN |
111627571 | Feb 2022 | CN |
112125281 | Feb 2022 | CN |
114086111 | Feb 2022 | CN |
215770541 | Feb 2022 | CN |
112695229 | Mar 2022 | CN |
112429772 | May 2022 | CN |
112479256 | May 2022 | CN |
111141670 | Jun 2022 | CN |
111627569 | Jul 2022 | CN |
114813222 | Jul 2022 | CN |
112530614 | Aug 2022 | CN |
112700895 | Aug 2022 | CN |
114842989 | Aug 2022 | CN |
112151197 | Sep 2022 | CN |
112891973 | Sep 2022 | CN |
113044378 | Sep 2022 | CN |
114288837 | Sep 2022 | CN |
217405118 | Sep 2022 | CN |
112551567 | Nov 2022 | CN |
112992389 | Nov 2022 | CN |
113603059 | Nov 2022 | CN |
112587989 | Dec 2022 | CN |
112863725 | Dec 2022 | CN |
112863726 | Dec 2022 | CN |
113241200 | Dec 2022 | CN |
2002147695 | May 2002 | JP |
10-2021-0008784 | Jan 2002 | KR |
WO 2015017928 | Feb 2015 | WO |
WO 2015094450 | Oct 2015 | WO |
WO 2017019620 | Feb 2017 | WO |
WO 2017032379 | Mar 2017 | WO |
WO 2017106509 | Jun 2017 | WO |
WO 2017171937 | Oct 2017 | WO |
WO 2017172177 | Oct 2017 | WO |
WO 2017172948 | Oct 2017 | WO |
WO 2017192611 | Nov 2017 | WO |
WO 2017199059 | Feb 2018 | WO |
WO 2018026536 | Feb 2018 | WO |
WO 2018027170 | Feb 2018 | WO |
WO 2018031148 | Feb 2018 | WO |
WO 2018031681 | Feb 2018 | WO |
WO 2018052529 | Mar 2018 | WO |
WO 2018064572 | Apr 2018 | WO |
WO 2018169588 | Oct 2018 | WO |
WO 2018213669 | Jan 2019 | WO |
WO 2019231971 | Jan 2020 | WO |
WO 2020123513 | Aug 2020 | WO |
WO 2022006169 | Jan 2022 | WO |
WO 2022076084 | Jun 2022 | WO |
WO 2022146446 | Jul 2022 | WO |
Entry |
---|
McFarlane et al., “Fission Product Volatility and Off-Gas Systems for Molten Salt Reactors”, US Department of Energy, Sep. 3, 2019 (Year: 2019). |
McFarlane et al. Fission Product Volatility and Off-Gas Systems for Molten Salt Reactors. US De-partment of Energy, Sep. 3, 2019. |
International Search Report and Written Opinion issued by the U.S. I.S.A. regarding International appli-cation No. PCT/US2020/059436 dated Feb. 2, 2021, 8 pages. |
Number | Date | Country | |
---|---|---|---|
20210138169 A1 | May 2021 | US |
Number | Date | Country | |
---|---|---|---|
62932887 | Nov 2019 | US |